There is only one oncolytic virus currently on the market, Amgen’s Imlygic (talimogene laherparepvec) launched in 2015, but its sales have been disappointing. But with 10 oncolytic viruses in ...

Among the frontrunners in the imlygic market is Amgen Inc., whose presence and activities significantly influence the course of the market. In 2024, North America was the largest region in the ...

It's not the first therapy in the oncolytic virus class to be approved around the world, as that accolade went to Amgen's Imlygic (talimogene laherparepvec), which was cleared by the FDA for the ...

There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.

Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Non-Small ... Talimogene laherparepvec (Imlygic) is a recombinant herpes simplex type-1 virus (HSV), acts ...

Imlygic (Talimogene laherparepvec ... Some of the major players include Daiichi Sankyo, Amgen, and Nanobiotix. These companies are driving innovation in the intratumoral cancer therapies market ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Investors with a lot of money to spend have taken a bearish stance on Amgen AMGN. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation ...

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Amgen's market standing. Stay informed and make well-considered decisions with our ...